gsk news

SOLID-TIMI 52 is a randomised, placebo-controlled, double-blind trial in men and women with ACS. The study will evaluate the clinical efficacy of long-term use of darapladib as compared with placebo when both are added to standard of care (which may include a statin, aspirin and blood pressure medications).

GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) today announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®)

GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine.

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify specific influenza virus strains using its real-time Polymerase Chain Reaction (PCR) technology platform, the Enigma ML (Mini Laboratory).

GlaxoSmithKline plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m). The business comprises a portfolio of 13 branded pharmaceuticals with annual sales in 2008 of $11.8m. This purchase is another step forward in GSK’s strategy to accelerate growth in emerging markets and signals a strong commitment to provide quality medicines to patients in the Middle East and North Africa.

GlaxoSmithKline plc (GSK) today announced an agreement with Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) to develop and market selected products across an extensive number of emerging markets, excluding India.

The first and only over-the-counter product for weight loss approved by the Food and Drug Administration will be available June 15.

On Wednesday, British drug maker GlaxoSmithKline PLC announced today that the United States Food and Drug Administration (FDA) approved its breast cancer treatment Tykerb to be used with Roche Holding's Xeloda in patients with advanced breast cancer or breast cancer that has spread to other parts of the body.

The Food and Drug Administration said GlaxoSmithKline's Alli is the first diet pill to be sold without a prescription.

US Department of Health and Human Services (HHS) awarded yesterday contracts GlaxoSmithKline, Novartis and Iomai Corp. valued at $132.5 million for developing a vaccine for bird flu.